Regeneron Pharmaceuticals Executive Compensation
Named Executive Officers — FY2025
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
Regeneron Pharmaceuticals's available SEC proxy filings disclose compensation for a single named executive officer: Leonard Schleifer (Chief Executive Officer).
Leonard Schleifer's total compensation rose 7% year-over-year, from $6.8M in FY2024 to $7.3M in FY2025.
Cash compensation (salary plus bonus) made up 27% of Regeneron Pharmaceuticals's FY2025 tracked executive pay, with stock awards accounting for 0%.
Among 78 other Healthcare companies in this dataset, Regeneron Pharmaceuticals's combined tracked executive pay of $7.3M ranks in the 37th percentile (industry median: $13.6M). Its highest-paid executive, Leonard Schleifer, ranks in the 54th percentile for top-executive pay in the sector (industry median: $6.0M).
Compensation figures on this page for Regeneron Pharmaceuticals come directly from its SEC DEF 14A proxy statement(s), filed with the SEC via EDGAR — not from crowdsourced or self-reported salary data.